Plasma homocysteine and gene polymorphisms associated with the risk of hyperlipidemia in northern Chinese subjects

Biomedical and Environmental Sciences

Volumn 21, Issue 6, 2008, Pages 514-520

  Lei, Huang ^a   Song, Xiao Mlng ^a   Zhu, Wen Li ^a   Li, Yong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Gene polymorphism; Homocysteine; Hyperlipidemia; Methionine synthase; Methylenetetra hydrofolate reductase

Indexed keywords

EID: 59849118511     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-3988(09)60011-8     Document Type: Article

References (30)

1. Brattstrom L, Wilcken D E, Ohrvik J, et al. (1998). Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98(23), 2520-2526.
2. McCully K S (1996). Homocysteine and vascular disease. Nat Med 2(4), 386-389.
3. den Heijer M, Rosendaal F R, Blom H J, et al. (1998). Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 80(6), 874-877.
4. Ueland P M, Refsum H, Beresford S A, et al. (2000). The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72(2), 324-332.
5. Boushey C J, Beresford S A, Omenn G S, et al. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Jama 274(13), 1049-1057.
6. Aguilar B, Rojas J C, Collados M T (2004). Metabolism of homocysteine and its relationship with cardiovascular disease. J Thromb Thrombolysis 18(2), 75-87.
7. Klerk M, Verhoef P, Clarke R, et al. (2002). MTHFR 677C - >T polymorphism and risk of coronary heart disease: a meta-analysis. Jama 288(16), 2023-2031.
8. Leclerc D, Campeau E, Goyette P, et al. (1996). Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 5(12), 1867-1874.
9. Xiao Y, Zhang Z T, Wang J B, et al. (2003). Effects of dietary intervention on hyperlipidemia in eight communities of Beijing, China. Biomed Environ Sci 16(2), 112-118.
10. te Poele-Pothoff M T, van den Berq M, Franken D G, et al. (1995). Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 32(Pt 2), 218-220.
11. Skibola C F, Smith M T, Kane E, et al. (1999). Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 96(22), 12810-12815.
12. Zhu W L, Cheng J, Dao J J, et al. (2004). Polymorphism of methionine synthase gene in nuclear families of congenital heart disease. Biomed Environ Sci 17(1), 57-64.
13. Nygard O, Vollset S E, Refsum H, et al. (1995). Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. Jama 274(19), 1526-1533.
14. Karmin O, Lynn E G, Chung Y H, et al. (1998). Homocysteine stimulates the production and secretion of cholesterol in hepatic cells. Biochim Biophys Acta 1393(2-3), 317-324.
15. Werstuck G H, Lentz S R, Dayal S, et al. (2001). Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 107(10), 1263-1273.
16. Liao D, Tan H, Hui R, et al. (2006). Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res 99(6), 598-606.
17. Li Y, Cheng J, Zhu W L, et al. (2005). Study of serum Hcy and polymorphisms of Hcy metabolic enzymes in 192 families affected by congenital heart disease. Beijing Da Xue Xue Bao 37(1), 75-80. (In Chinese)
18. Frosst P, Blom H J, Milos R, et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1), 111-113.
19. Yilmaz H, Agachan B, Isbir T, et al. (2003). Is there additional effect of MTHFR C677T mutation on lipid abnormalities in renal allograft recipients? Transplant Proc 35(4), 1390-1392.
20. Zuntar I, Antoljak N, Vrkic N, et al. (2006). Association of methylenetetrahydrofolate (MTHFR) and apolipoprotein E (apo E) genotypes with homocysteine, vitamin and lipid levels in carotid stenosis. Coll Antropol 30(4), 871-878.
21. Veerkamp M J, de Graaf J, den Heijer M, et al. (2003). Plasma homocysteine in subjects with familial combined hyperlipidemia. Atherosclerosis 166(1), 111-117.
22. Zhang G S, Dai C W (2001). Gene polymorphisms of homocysteine metabolism related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases. Thrombosis Research 104(3), 189-195.
23. Laraqui A, Allami A, Carrie A, et al. (2006). Influence of methionine synthase (A2756G) and methionine synthase reductase (A66G) polymorphisms on plasma homocysteine levels and relation to risk of coronary artery disease. Acta Cardiol 61(1), 51-61.
24. Harmon D L, Shields D C, Woodside J V, et al. (1999). Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 17(4), 298-309.
25. Jacques P F, Bostom A G, Selhub J, et al. (2003). Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study. Atherosclerosis 166(1), 49-55.
26. Hyndman M E, Bridge P J, Warnica J W, et al. (2000). Effect of heterozygosity for the methionine synthase 2756 A > G mutationon the risk for recurrent cardiovascular events. Am J Cardiol 86(10), 1144-1146, A9.
27. Morita H, Kurihara H, Sugiyama T, et al. (1999). Polymorphism of the methionine synthase gene-association with homocysteine metabolism and late-onset vascular diseasesin the Japanese population. Arteriol Thromb Vasc Biol 19(2), 298-302.
28. Rafique S, Guardascione M, Osman E, et al. (1992). Reversal of extrahepatic membrane cholesterol deposition in patients with chronic liver diseases by S-adenosyl-L-methionine. Clin Sci (Lond) 83(3), 353-356.
29. Chawla R K, Bonkovsky H L, Galambos J T (1990). Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease. Drugs 40(Suppl 3), 98-110.
30. Klerk M, Lievers K J, Kluijtmans L A, et al. (2003). The 2756A>G variant in the gene encoding methionine synthase: its relation with plasma homocysteine levels and risk of coronary heartdisease in a Dutch case-control study. Thromb Res 110(2-3), 87-91.